Synthesis of Water Soluble Chitosan-Artemisinin Conjugate

DAN XIAO, BO YANG*, XUE-MIN YANG, DONG YI, XIA-LI LIAO, JIAN YANG and CHUAN-ZHU GAO

Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, P.R. China

*Corresponding author: Tel: +86 13064281879; E-mail: yangbo6910@sina.com; xiaodan19871124@yahoo.com.cn

(Received: 24 July 2012;

Accepted: 18 February 2013)

AJC-13030

The conjugate was prepared through a series of reactions, starting from the hydrogenation of artemisinin and then acylation, hydrolysis and condensation. The solubility of chitosan-artemisinin conjugate was evaluated and compared with a normal commercially available artemisinin. The results indicated that the conjugate had much higher solubility in comparison with artemisinin. The method reported in this paper provides a good yield of chitosan-artemisinin conjugate, chitosan-artemisinin could be attributed to increasing the bioavailability in artemisinin delivery.

Key Words: Artemisinin, Chitosan, Conjugate, Water soluble.

INTRODUCTION

Malaria represents one of the most dangerous diseases in many tropical and subtropical areas, as more than 500 million people result infected annually and as one person (mostly children) is estimated to die in every 12 s due to the consequences of this infection¹. Artemisinin (Fig. 1) is the active principle of the Chinese traditional antimalarial drug *Artemisia annua* L². It has semisynthetic derivatives, such as dihydro-artemisinin and artemether, are effective against both chloroquine-sensitive and chloroquine-resistant *P. falciparum* and are clinically used for the treatment of cerebral malaria³. In recent years, Artemisinin has been shown to be effective in killing cancer cells⁴⁻⁶. However, Artemisinin is a poorly water soluble drug and has low bioavailability by oral administration due to slow drug dissolution and decomposition in stomach and intestine⁷.

Chitosan (Fig. 2) which is a natural cationic polysaccharide composed by β -(1-4)-linked glucosamine units together with some N-acetyl-d-glucosamine units, is obtained by exhaustive deacetylation of chitin⁸. Owing to the favourable biodegradable, nontoxic and antimicrobial properties, chitosan has been used in different biomedical and drug delivery applications^{9,10}.

Chen and Lin¹¹ have reported of artemisinin nanocapsules as anticancer drug delivery systems. Usuda *et al.*¹² use several kinds of cyclodextrins as solubilizers was examined, our previous work indicated that hydroxypropyl-cyclodextrin complexed with artemether and the complex produces a 1.81-fold enhancement in apparent bioavailability compared to

artemether¹³. In this paper, we have focused on the solubilization and stabilization effect of conjugate, after hydrogenation, substitution and condensation. Results show that have much higher solubility compared to artemisinin. The method reported in this paper provides a good yield of the chitosan-artemisinin conjugate and it could be attributed to increasing the bioavailability in artemisinin delivery.

Fig. 1. Structure of the artemisinin

Fig. 2. Structure of the chitosan

EXPERIMENTAL

Artemisinin was obtained from Kunming Pharmaceutical Corporation (PC > 99 %) in Yunnan Province, P. R. China. Chitosan was commercially available ($\overline{M}_n = 1800$, $\overline{M}_w/\overline{M}_n = 1.31$) (Nanjing Reagent Factory). N,N-Dimethyl formamide (DMF) was predried over calcium hydride for 2 days and then distilled under a reduced pressure prior to use. 4-Dimethyl-amiopyridine (DMAP) was commercially available (Chengdu Reagent Factory). Dicyclohexylcarbodiimide (DCC) was

commercially available (Shanghai Reagent Factory) and used without further purification. Other chemicals and solvents were of analytical-reagent grade and deionized double-distilled water was used throughout the study.

All reactions were monitored by TLC, melting points were determined by the capillary method without correction. ^1H NMR spectra and MS data were recorded on a Bruker DRX 500 NMR spectrometer and a ZAB-2F mass spectrometer, respectively.

Synthesis of dihydroartemisinin (2): To a stirred solution of artemisinin 1.500 g (5 mmol) in MeOH (130 mL) and maintained at 0–5 °C, the mixture was added NaBH_4 1.300 g (24 mol), it was stirred at 0–5 °C for 1 h. Acetic acid was added to adjust the pH = 7, then it was added to cold water (100 mL) and stirred for 15 min at room temperature. The white precipitate was collected and washed with H_2O -MeOH (2:1, 2 mL $\times$ 200 mL). The wet crops were pooled and dissolved in CH_2Cl_2 (4 mL $\times$ 30 mL). After drying (40 g MgSO_4) and evaporation of the solvent, the solution are dried over anhydrous sodium sulfate and solvent was removed *in vacuo* to afford white solid (1.260 g) 84 % yield. m.p. 147–150 (lit¹⁴ 149–153 °C). ^1H NMR (500 MHz, CDCl_3): 5.61–5.39 (m, 1H, O-CH-O), 5.30–4.76 (d, 1H, CHOH), 2.63 (m, 0.5H, CHCH_3), 0.91–1.02 (m, 6H, CHCH_3), MS (m/z): 284 (M^+).

Synthesis of artesunate (3): To a solution of succinic anhydride (1.260 g, 12.6 mmol) in dry acetone (10 mL), triethylamine (1.23 mmol), dihydroartemisinin (2) (500 mg, 1.8 mmol) was added dropwise at room temperature over a period of 9 h under an N_2 atmosphere. The resulting solution was poured into water (80 mL) and then neutralized to pH 3–4 with 1 M HCl, the mixture was cooled to 0 °C, the wet crops were pooled and dissolved in CH_2Cl_2 (4 L $\times$ 30 L). And then the precipitate was filtrated, dried *in vacuo* to obtain **3** (275 mg) white solid in 38 % yield; m.p. 142–146 °C (lit¹⁵ 139–143 °C). ^1H NMR (500 MHz, CDCl_3): 5.80 (d, 1H, O-CH-OC=O), 5.44 (s 1H O-CH-O) 2.64–2.78 (m, 4H, O=CCH₂), 2.55–2.60 (m, 1H, CHCH_3), 2.34–2.42 (m, 1H), 0.99–1.03 (m, 1H), 0.97 (d, 3H, CHCH_3), 0.85 (d, 3H, CHCH_3). MS(m/z): 384 (M^+).

Synthesis of chitosan-artemisinin conjugate (4): To solution of artesunate (**3**) 384 mg (1.0 mmol) in dry DMF (50 mL), Chitosan 180 mg (0.1 mmol) and dicyclohexylcarbodiimide (DCC) 226 mg (1.1 mmol) was added. The reaction mixture was stirred for 2 days in an ice bath and another 2 days at room temperature and then allowed to stand for 1 h. The precipitate was removed by filtration and the filtrate was poured into 300 mL of acetone. The precipitate was collected

and subsequently purified on a Sephadex G-25 column with water as eluent. after the residue was dried *in vacuo*, we got the yellow solid (408 mg) in 75 % yield. ^1H NMR (500 MHz, D_2O + HCl): 5.80–5.44 (m, O-CH-O), 2.64–2.78 (m, O=CCH₂), 3.649–3.874 (m, H-3, H-4, H-5, H-6 of chitosan), 3.280–3.312 (H-2 of chitosan), 0.97 (d, CHCH_3), 0.87 (m, CHCH_3).

Measurement of water solubility: The water solubility of chitosan-artemisinin conjugate was assessed by preparation of its saturated aqueous solution¹⁶. An excess amount of complex was put in 5 mL of water (pH *ca.* 7) and the mixture was stirred for 1 h. After removing the insoluble substance by filtration, the filtrate is evaporated under reduced pressure to dryness and the residue is dosed by weighing method.

RESULTS AND DISCUSSION

Two kinds of chitosan-artemisinin conjugate that contain different amounts of artemisinin were synthesized according to the synthetic route shown in Fig. 3. The results are summarized in Table-1. The chitosan-artemisinin conjugate in the polymers prepared in this experiment was 0.60 and 0.75 mol-%, respectively and could be controlled by varying the feed ratio between chitosan and artesunate (**3**). All the polymers obtained showed high water solubility. The chemical composition of the polymers was confirmed by means of ^1H NMR. Fig. 4 shows a representative ^1H NMR spectrum of the chitosan-artemisinin conjugate, demonstrating the presence of covalently bound chitosan amide in the polymers. We can calculate the produced rate, according to ^1H NMR spectrum Table-2 show that the solubility of artemisinin is 0.084 g/dL, the chitosan-artemisinin conjugate (**4**) was 3.123 g/dL. It is better than previously reported data¹⁵.

TABLE-1
SYNTHETIC RESULTS DERIVED FROM
CHITOSAN-ARTEMISININ CONJUGATE

Molar feed ratio chitosan/artesunate (3)	$\overline{\text{Mn}}$ (g/mol) ^a	$\overline{\text{Mn}}$ (g/mol) ^b	Yield (mol %)
1:8	4728	2931	62
1:10	5460	4095	75

^aTheoretical value. ^bCalculated from the peak integration of ^1H NMR spectra.

TABLE-2
PHYSICOCHEMICAL PROPERTIES OF ARTEMISININ
AND CHITOSAN-ARTEMISININ CONJUGATE

Compound	m.p. (°C)	Solubility (g/dL) ^a
Artemisinin	156	0.084
Chitosan-artemisinin conjugate	–	3.123

^aIn water at 25 °C.

Reagents and conditions: (a) NaBH_4 (b) anhydride (c) DCC

Fig. 3. Synthesis of chitosan/artemisinin derivatives

Fig. 4. ^1H NMR spectrum of chitosan-artemisinin conjugate (4) in D_2O

Conclusion

We successfully prepared conjugate after hydrogenation, substitution and condensation. Results show that have much higher solubility compared to artemisinin. This could be attributed to increasing the bioavailability in artemisinin delivery.

ACKNOWLEDGEMENTS

This work was supported by National Natural Science Foundation of China (NNSFC) (No. 21062009), Science Foundation of Kunming University of Science and Technology, and the Natural Science Foundation of Yunnan Province (No. 2009ZC045M), Meanwhile, all authors expressed their deep thanks to the Analysis and Testing Foundation of Kunming University of Science and Technology.

REFERENCES

1. G. Marshall, *Science*, **290**, 428 (2000).
2. D.L. Klayman, *Science*, **228**, 1049 (1985).
3. X.D. Luo and C.C. Shen, *Med. Res. Rev.*, **7**, 29 (1987).
4. H. Lai and N.P. Singh, *Cancer Lett.*, **91**, 41 (1995).
5. T. Efferth, H. Dunstan and A. Sauerbrey, H. Miyachi and C.R. Chitambar, *Int. J. Oncol.*, **18**, 767 (2001).
6. T. Efferth, A. Benakis, M.R. Romero, M. Tomicic, R. Rauh, D. Steinbach, R. Häfer, T. Stamminger, F. Oesch, B. Kaina and M. Marschall, *Free Radic. Biol. Med.*, **37**, 998 (2004).
7. I. Nakase, H. Lai, N.P. Singh and T. Sasaki, *Int. J. Pharm.*, **28**, 354 (2008).
8. N. Bhattarai, J. Gunn and M.Q. Zhang, *Adv. Drug. Deliv. Rev.*, **62**, 83 (2010).
9. Y.B. Schuetz, R. Gurny and O. Jordan, *Eur. J. Pharm. Biopharm.*, **68**, 19 (2008).
10. J. Wu and M. Sailor, *Adv. Funct. Mater.*, **19**, 73 (2009).
11. Y.F. Chen and X.F. Lin, *Exp. Nano. Pharm. Res.*, **5**, 316 (2009).
12. M. Usuda, T. Endo, H. Nagase and K. Tomono and H. Ueda, *Drug Dev. Ind. Pharm.*, **26**, 613 (2000).
13. B. Yang, J. Lin, Y. Chen and Y. Liu, *Bioorg. Med. Chem.*, **17**, 6311 (2009).
14. A. Brossi, B. Venugopalan, G.L. Dominguez, H.J. Yeh, J.L. Flippen-Anderson, P. Buchs, X.D. Luo, W. Milhous and W. Peters, *J. Med. Chem.*, **31**, 645 (1988).
15. R.K. Haynes, H.-W. Chan, M.-K. Cheung, W.-L. Lam, M.-K. Soo, H.-W. Tsang, A. Voerste and I.D. Williams, *Eur. J. Org. Chem.*, 113 (2002).
16. R.C. Petter, J.S. Salek, C.T. Sikorski, R.C. Petter, J.S. Salek, C.T. Sikorski, G. Kumaravel and F.T. Lin, *J. Am. Chem. Soc.*, **112**, 3860 (1990).